for more information
Pipeline & Products
| COMPOUND | DISCOVERY | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|---|
| SNS-595 | |||||
| Acute Myeloid Leukemia |  |
|
|
|
|
| Platinum-Resistant Ovarian Cancer | |
|
|
|
|
| SNS-032 | |||||
| Chronic Lymphocytic Leukemia and Multiple Myeloma | |
|
|
||
| SNS-314 | |||||
| Advanced Solid Tumors | |
|
|
||
| Discovery | |||||
| Aurora A Cancer |
|
||||
| Partnered Programs | |||||
| Raf (Biogen IDEC) Cancer | |
||||
| BACE (Merck) Alzheimer's | |
|
|||
| Cathepsin S (J&JPRD) Inflammation | |
Get resources and information for patients and caregivers
Phase 2 study of SNS-595 as a treatment for patients with acute myeloid leukemia
Clinical Trial Info MOA SNS-595Phase 2 study of SNS-595 as a treatment for women with platinum-resistant ovarian cancer
Clinical Trial Info MOA SNS-595Phase 1 study of SNS-032 for patients with either Chronic Lymphocytic Leukemia (CLL) or Multiple Myeloma (MM)
Clinical Trial Info MOA SNS-032Phase 1 study of SNS-314 for patients with a cancer of solid organ tissue
Clinical Trial Info MOA SNS-595Oncology program focusing on selective inhibitors of Aurora A kinase
More informationSunesis collaborating with Biogen Idec on the advancement of a Raf kinase inhibitor into development
More informationSunesis collaborated with Merck to discover inhibitors of Beta Amyloid Converting Enzyme (BACE)
More informationSunesis collaborated with Johnson & Johnson PRD to discover small molecule inhibitors of Cathepsin S
More information
